On April 13, 2021, the U.S. Food and Drug Administration (FDA) approved a supplemental application for Tecentriq (atezolizumab), a drug developed by Genentech Inc. This approval pertains to the drug's efficacy, as indicated by the supplemental application.
Background
Atezolizumab (Tecentriq) is an established therapeutic agent. This supplemental approval specifically addresses an efficacy aspect of the drug, building upon its existing profile.
What this means
The FDA's approval of this supplemental application for Tecentriq (atezolizumab) indicates that the agency has reviewed additional efficacy data submitted by Genentech Inc. This type of approval typically expands or refines the understanding of a drug's effectiveness, potentially leading to updated prescribing information or broader clinical utility. Without specific details on the indication or population, the precise clinical implications for this supplemental approval are not detailed in the available data.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for supplemental application BLA 761034 S-41 for Tecentriq (atezolizumab) was granted on April 13, 2021, and is publicly accessible on accessdata.fda.gov.